Results

1–10 of 182 results for Diabetic Macular Edema

Reduced Rates of Diabetic Retinopathy Complications With Use of Continuous Glucose Monitoring: A Multicenter Population-Based Study
Amer F Alsoudi, MD
Annual Meeting Talks
2025
Risk Factors for Diabetic Retinopathy Progression During Pregnancy
Majda Hadziahmetovic, MD
Annual Meeting Talks
2025
Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-VEGF Therapy for Diabetic Macular Edema
Judy E. Kim, MD, FASRS
Annual Meeting Talks
2025
Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2025
Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Dante Joseph Pieramici, MD
Annual Meeting Talks
2025
Efficacy and Safety Outcomes Over 12 Weeks With OCS-01 Eye Drops in DME From DIAMOND-Stage 1 Trial:Focus on Subgroup by Prior Treatment Status
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2025
Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established RabbitModel
Dilsher S. Dhoot, MD
Annual Meeting Talks
2025
A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept orFaricimab, in Diabetic Macular Edema
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2025
Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With BilateralDiabetic Macular Edema (DME)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2025
Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults WithDiabetic Macular Edema
David RP Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS
Annual Meeting Talks
2025